Skip to main content
. Author manuscript; available in PMC: 2020 May 22.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 May 13;11(20):18074–18089. doi: 10.1021/acsami.9b01343

Figure 6.

Figure 6.

(A) STAT-3 inhibition study in MDA-MB231 cells at 48h incubation time point. Nifuroxazide was used in form of small molecule, Pro-nifuroxazide and prodrug nanoparticle at a concentration of 20 μM. Cells were incubated for 48h before collecting the RNA and performing PCR studies. Pro-nifuroxazide nanoparticle showed maximum inhibition in STAT-3 expression followed by Pro-nifuroxazide while nifuroxazide showed the minimum inhibition. (B) STAT-3 protein inhibition study in MDA-MB231 cells at 48h incubation time point. Nifuroxazide, Pro-nifuroxazide and Pro-nifuroxazide nanoparticle at final concentration of 20 μM were used. Cells were incubated for 48h before collecting the total protein and performing Western Blot studies (C). Pro-nifuroxazide nanoparticle showed maximum inhibition in STAT-3 expression followed by proPro-nifuroxazide while nifuroxazide alone showed the minimum inhibition. Biostatistical analysis was performed using ONE Way ANOVA with post Bonferroni test. Here * represents p values <0.05 and 0.001, respectively.